메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

New Board, New Strategy: Home Control Taps Global Perspectives to Drive Smart Healthcare Expansion

HONG KONG, Sept. 6, 2025 -- Traditionally in Hong Kong's capital market, Home Control (1747.HK) has often been described as a "hidden gem". The company has maintained a solid financial track record with consistent dividend payouts, yet has rarely been in the market spotlight. Recently, the appointment of several new directors has drawn significant investor attention, propelling the share price to record highs since listing, with a year-to-date gain of more than tenfold. The newly appointed board members bring extensive experience and strong credentials across smart healthcare
- 김갑성 기자
- 2025-09-06 02:07
Huadong Medicine Announces Positive Preliminary Results from a Phase Ⅰ study of HDM2005, a ROR1-Targeting ADC

HANGZHOU, China, Sept. 5, 2025 -- Huadong Medicine Co., Ltd. (hereinafter referred to as "Huadong Medicine") today announced positive preliminary results from a Phase I study of HDM2005, an independently developed Class 1 innovative antibody–drug conjugate (ADC) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) or classical Hodgkin lymphoma (cHL). The results showed that HDM2005 demonstrated promising efficacy with a favorable safety and tolerability profile in B-NHL and cHL, which will suppo
- 김갑성 기자
- 2025-09-05 21:38
'CART BP pro' Opens a New Paradigm in Blood Pressure Management, Maintaining Accuracy Across Arm Positions

SEOUL, South Korea, Sept. 5, 2025 -- At the European Society of Cardiology (ESC) Congress 2025, held in Madrid from August 29 to September 1, Sky Labs presented new clinical findings on CART BP pro, its cuffless, ring-type blood pressure monitor. The device demonstrated consistent accuracy even when the arm was positioned below heart level, meeting the rigorous validation requirements set by the European Society of Hypertension (ESH). The ESH recommends six validation tests for cuffless blood pressure devices, namely the static test for absolute accuracy, the device pos
- 김갑성 기자
- 2025-09-05 20:48
Health In Tech Strengthens Leadership Team to Accelerate AI Innovation and Drive Enterprise Revenue Growth

STUART, Fla., Sept. 5, 2025 -- Health In Tech (Nasdaq: HIT), an Insurtech platform company backed by third-party AI technology, today announced strategic leadership appointments designed to advance AI utilization and accelerate company growth. Dustin Plantholt, formerly our Chief Growth Officer, has been appointed Chief Artificial Intelligence & Marketing Officer, where he will spearhead the company's AI strategy and lead enterprise-wide marketing initiatives. In addition, Zain Hasan has joined Health In Tech as Head of Revenue and Growth responsible for scali
- 황정호 기자
- 2025-09-05 19:30
FUTUONING Sets Sail Commercially with First Prescriptions Across China

SHANGHAI, Sept. 5, 2025 -- These days, the first prescriptions of FUTUONING (fovinaciclib citrate capsules) were issued by more than ten hospitals across China, including Fudan University Shanghai Cancer Center, Cancer Hospital of the Chinese Academy of Medical Sciences, The First Affiliated Hospital Zhejiang University School of Medicine, The First Affiliated Hospital of Anhui Medical University, Shandong Cancer Hospital, Shanghai Tenth People's Hospital, Nanjing Drum Tower Hospital and The Affiliated Hospital of Qingdao University. FUTUONING, a CDK4/6 inhibitor, is indicated in combi
- 김갑성 기자
- 2025-09-05 18:12
Senhwa Biosciences CX-5461 Secures NCI Support to Advance into MYC-Driven Lymphoma, Driving Cross-Cancer and Global Licensing Value

TAIPEI and SAN DIEGO, Sept. 5, 2025 -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) has granted IND clearance for its innovative drug candidate Pidnarulex(CX-5461) ina Phase 1b/2 clinical trial in patients with B-cell lymphoma subtypes that harbors MYC gene aberrations. Given that nearly 30% of all cancers are associated with MYC oncogene overexpression, the clinical development of CX-5461 is generating significant anticipation. If the trial delivers positive resu
- 김갑성 기자
- 2025-09-05 16:46
Immunofoco Earns Spot on Forbes Asia 100 to Watch 2025 List for Leading New Wave in Solid Tumor Cell Therapy

SHANGHAI, Sept. 5, 2025 -- Immunofoco, a clinical-stage biotechnology company, focused on developing novel cell therapies for solid tumors, has been selected for the prestigious "Forbes Asia 100 to Watch 2025" list. This annual list, compiled by the editors of Forbes Asia, spotlights outstanding small companies and startups across the Asia-Pacific region that are recognized for their innovation and strong growth potential. Immunofoco stands out as one of only nine companies from Mainland China and one of two in the Biotechnology & Healthcare sector on the list, highlighti
- 김갑성 기자
- 2025-09-05 16:09
Medidata Secures a Leader Position in Everest Group's PEAK Matrix® Assessment for eCOA, Driving the New Patient Experience Forward

Medidata eCOA was the highest Leader recognized in the evaluation, supporting over 1M+ patients and reducing study build timeline by up to 50% compared to the industry standard SINGAPORE, Sept. 5, 2025 -- Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, has been recognized as a Leader in Everest Group's Life Sciences Electronic Clinical Outcome Assessment (eCOA) Products PEAK Matrix® Assessment 2025. The report assessed 19 providers based on their demonstrated success in delivering products and drivin
- 김갑성 기자
- 2025-09-05 10:00
Smartee and Dental Monitoring Partner to Simplify Refinement Workflows for Orthodontists

SHANGHAI, Sept. 5, 2025 -- Smartee Denti-Technology, a leading innovator in clear aligner solutions, and Dental Monitoring, the global leader in AI-powered remote monitoring for orthodontics, today announced a new integration designed to simplify and accelerate refinement workflows for orthodontists and dental professionals. Traditionally, refinement in clear aligner treatment requires patients to visit their orthodontist's office for an intraoral scan. The scan is then submitted to Smartee to generate a new treatment plan. While precise, this process often adds extra appointme
- 김갑성 기자
- 2025-09-05 09:30
Olympus Announces Distribution Partnership with MacroLux Medical for Single-Use Urology Products

WESTBOROUGH, Mass., Sept. 4, 2025 -- Olympus Corp., a global medical technology company committed to making people's lives healthier, safer and more fulfilling, announced today an exclusive global distribution agreement with MacroLux Medical Technology Co., Ltd. to distribute single-use urology products. The agreement includes multiple single-use cystoscopes, ureteroscopes and suction access sheaths. These devices are used to access and visualize the bladder and urinary tract to diagnose and treat urinary diseases and disorders such as kidney stones. "We ar
- 김갑성 기자
- 2025-09-04 22:12

이전

61 62 63 64 65 66 67 68 69 70

많이 본 기사

최근기사

2025-11-05_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 05일 09시 20분